• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Alzheimers Res Ther . COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients

tetano

Editor, Senior Moderator
Alzheimers Res Ther


. 2021 Apr 10;13(1):77.
doi: 10.1186/s13195-021-00820-9.
COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients


Agathe Vrillon[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Elsa Mhanna[SUP] #[/SUP][SUP] 4 [/SUP], Cl?ment Aveneau[SUP] 5 6 [/SUP], Manon Lebozec[SUP] 7 [/SUP], Lina Grosset[SUP] 6 8 [/SUP], Diane Nankam[SUP] 4 [/SUP], Fernanda Albuquerque[SUP] 4 [/SUP], Raphaelle Razou Feroldi[SUP] 4 [/SUP], Barbara Maakaroun[SUP] 4 [/SUP], Iana Pissareva[SUP] 4 [/SUP], Dalenda Cherni Gherissi[SUP] 4 [/SUP], Julien Azuar[SUP] 5 8 9 [/SUP], V?ronique Fran?ois[SUP] 10 [/SUP], Claire Hourr?gue[SUP] 6 8 [/SUP], Julien Dumurgier[SUP] 6 8 [/SUP], Lisette Volpe-Gillot[SUP] 4 [/SUP], Claire Paquet[SUP] 5 6 [/SUP]



Affiliations

Abstract

Background: There is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19).
Method: We conducted a prospective study in 2 gerontologic COVID units in Paris, France, from March 14, 2020, to May 7, 2020. Patients with dementia hospitalised for confirmed COVID-19 infection were systematically enrolled. A binary logistic regression analysis was performed to identify factors associated with mortality at 21 days.
Results: We included 125 patients. Median age was 86 (IQI 82-90); 59.4% were female. Most common causes of dementia were Alzheimer's disease, mixed dementia and vascular dementia. 67.2% had ? 2 comorbidities; 40.2% lived in a long-term care facility. The most common symptoms at COVID-19 onset were confusion and delirium (82.4%), asthenia (76.8%) and fever (72.8%) before polypnea (51.2%) and desaturation (50.4%). Falls were frequent at the initial phase of the disease (35.2%). The fatality rate at 21 days was 22.4%. Chronic kidney disease and CRP at admission were independent factors of death. Persisting confusion, mood and behavioural disorders were observed in survivors (19.2%).
Conclusion: COVID-19 in demented individuals is associated with severe outcome in SARS-CoV-2 infection and is characterised by specific clinical features and complications, with confusion and delirium at the forefront. COVID-19 testing should be considered in front of any significant change from baseline.

Keywords: COVID-19; Dementia; Mortality; Prognostic factors; SARS-CoV-2.
 
Back
Top Bottom